TCM
TCRR

Tang Capital Management’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Tang Capital Management’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,399,745
Closed -$5.1M – 121
2023
Q1 		$5.1M Buy
3,399,745
+660,798
+24% +$890K 0.76% 40
2022
Q4 		$2.74M Sell
2,738,947
-1,002,659
-27% -$1.35M 0.4% 54
2022
Q3 		$6.74M Buy
3,741,606
+100,000
+3% +$290K 0.83% 38
2022
Q2 		$10.6M Buy
3,641,606
+641,606
+21% +$1.58M 1.6% 19
2022
Q1 		$8.28M Buy
+3,000,000
New +$9.44M 1.66% 17

Tang Capital Management's TCRR Position: Q2 2023 in Review

Tang Capital Management sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 3,399,745 shares — an estimated $5.1M sold.

Tang Capital Management first reported a position in TCRR in Q1 2022 and held it in 5 quarters. The position peaked at $10.6M in Q2 2022. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.

  • Tang Capital Management reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Tang Capital Management sold 3,399,745 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $5.1M.
  • Tang Capital Management first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2022 and held it in 5 quarters.
  • Tang Capital Management's TCR2 Therapeutics Inc. Common Stock position peaked at $10.6M in Q2 2022.
  • 0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.

Based on Tang Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.